IL92075A - Preparations for the prevention of over-stretching and its treatment and diagnosis, with potassium salts without halogen - Google Patents

Preparations for the prevention of over-stretching and its treatment and diagnosis, with potassium salts without halogen

Info

Publication number: IL92075A
Authority: IL; Israel
Prior art keywords: potassium; salt; hypertension; administration; bicarbonate
Prior art date: 1988-10-21

Application number

IL9207589A

Other languages

English (en)

Hebrew (he)

Other versions

IL92075A0 (en

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-21

Filing date

1989-10-22

Publication date

1995-07-31

1989-10-22 Application filed by Univ California filed Critical Univ California

1990-07-12 Publication of IL92075A0 publication Critical patent/IL92075A0/xx

1995-07-31 Publication of IL92075A publication Critical patent/IL92075A/en

Links

206010020772 Hypertension Diseases 0.000 title claims abstract description 48
-1 halide potassium salts Chemical class 0.000 title claims abstract description 14
238000011282 treatment Methods 0.000 title claims description 19
238000003745 diagnosis Methods 0.000 title claims description 8
230000002265 prevention Effects 0.000 title claims description 7
239000000203 mixture Substances 0.000 title description 21
229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 45
239000011736 potassium bicarbonate Substances 0.000 claims abstract description 39
235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 39
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 39
150000003839 salts Chemical class 0.000 claims abstract description 37
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 20
239000011591 potassium Substances 0.000 claims abstract description 20
229910052700 potassium Inorganic materials 0.000 claims abstract description 20
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims abstract description 18
229910000160 potassium phosphate Inorganic materials 0.000 claims abstract description 9
235000011009 potassium phosphates Nutrition 0.000 claims abstract description 9
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 20
229960003975 potassium Drugs 0.000 claims description 19
230000037396 body weight Effects 0.000 claims description 14
235000015872 dietary supplement Nutrition 0.000 claims description 12
239000001508 potassium citrate Substances 0.000 claims description 11
229960002635 potassium citrate Drugs 0.000 claims description 11
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 11
235000011082 potassium citrates Nutrition 0.000 claims description 11
239000001103 potassium chloride Substances 0.000 claims description 10
235000011164 potassium chloride Nutrition 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 6
239000004224 potassium gluconate Substances 0.000 claims description 6
229960003189 potassium gluconate Drugs 0.000 claims description 6
235000013926 potassium gluconate Nutrition 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 2
229940094025 potassium bicarbonate Drugs 0.000 claims 4
229940093916 potassium phosphate Drugs 0.000 claims 4
241000282412 Homo Species 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
230000036772 blood pressure Effects 0.000 abstract description 27
238000000034 method Methods 0.000 abstract description 22
235000005911 diet Nutrition 0.000 abstract description 17
230000000378 dietary effect Effects 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 16
239000011780 sodium chloride Substances 0.000 description 16
150000004820 halides Chemical class 0.000 description 13
230000037213 diet Effects 0.000 description 11
230000035488 systolic blood pressure Effects 0.000 description 11
230000035487 diastolic blood pressure Effects 0.000 description 10
239000011734 sodium Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
230000004872 arterial blood pressure Effects 0.000 description 7
159000000001 potassium salts Chemical class 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
208000007530 Essential hypertension Diseases 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000003276 anti-hypertensive effect Effects 0.000 description 5
230000001631 hypertensive effect Effects 0.000 description 5
238000011084 recovery Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000002354 daily effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
239000013589 supplement Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003205 diastolic effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
235000021023 sodium intake Nutrition 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000004531 blood pressure lowering effect Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000021962 pH elevation Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000006187 pill Substances 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000000304 vasodilatating effect Effects 0.000 description 2
235000020795 whole food diet Nutrition 0.000 description 2
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000002682 Hyperkalemia Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
208000004531 Renal Artery Obstruction Diseases 0.000 description 1
206010038378 Renal artery stenosis Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000003192 autonomic ganglia Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
229960001523 chlortalidone Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000009110 definitive therapy Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004882 diastolic arterial blood pressure Effects 0.000 description 1
235000007882 dietary composition Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
238000011457 non-pharmacological treatment Methods 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
150000003112 potassium compounds Chemical class 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
238000009138 potassium supplementation Methods 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
230000002315 pressor effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000004873 systolic arterial blood pressure Effects 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Display Devices Of Pinball Game Machines (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL9207589A 1988-10-21 1989-10-22 Preparations for the prevention of over-stretching and its treatment and diagnosis, with potassium salts without halogen IL92075A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26085688A	1988-10-21	1988-10-21

Publications (2)

Publication Number	Publication Date
IL92075A0 IL92075A0 (en)	1990-07-12
IL92075A true IL92075A (en)	1995-07-31

Family

ID=22990921

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL9207589A IL92075A (en)	1988-10-21	1989-10-22	Preparations for the prevention of over-stretching and its treatment and diagnosis, with potassium salts without halogen
IL9207689A IL92076A (en)	1988-10-21	1989-10-22	Preparations for the prevention of bone pores, and for their treatment, with potassium salts that cause an alkaline reaction

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL9207689A IL92076A (en)	1988-10-21	1989-10-22	Preparations for the prevention of bone pores, and for their treatment, with potassium salts that cause an alkaline reaction

Country Status (13)

Country	Link
US (1)	US5804204A (de)
EP (3)	EP0720855A3 (de)
JP (2)	JP2948247B2 (de)
KR (2)	KR0178033B1 (de)
AT (1)	ATE145825T1 (de)
AU (2)	AU635231B2 (de)
CA (2)	CA2001123C (de)
DE (2)	DE68927519T2 (de)
DK (2)	DK175840B1 (de)
HU (2)	HU208923B (de)
IL (2)	IL92075A (de)
WO (2)	WO1990004402A1 (de)
ZA (2)	ZA898017B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674529A (en) *	1995-06-06	1997-10-07	Church & Dwight Co., Inc.	Alkalinizing potassium salt controlled release preparations
AT408416B (de) *	1996-07-19	2001-11-26	Norbert Fuchs	Pharmazeutische bzw. diätetische zusammensetzungen
WO2003086423A1 (en) *	2002-04-05	2003-10-23	Btg International Limited	Low-dose potassium supplementation for the prevention and treatment of hypertension
EP1350515A1 (de) *	2002-04-05	2003-10-08	Btg International Limited	Niedrig-dosierte Kaliumergänzung zur Vorbeugung und Therapie der Hypertonie
US20040202726A1 (en) *	2003-04-10	2004-10-14	Deshay Samuel L.	Topical blood pressure composition
US10251909B2 (en) *	2007-02-09	2019-04-09	Board Of Regents, The University Of Texas System	Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension
US20090022853A1 (en) *	2007-07-16	2009-01-22	Conopco, Inc., D/B/A Unilever	Beverage
MX2010008625A (es) *	2008-02-06	2010-09-14	Campbell Soup Co	Metodos y composiciones para reducir el contenido de sodio en productos alimenticios.
ATE537710T1 (de) *	2008-09-05	2012-01-15	Unilever Nv	Getränke, die kalium enthalten
WO2022073459A1 (zh) *	2020-10-09	2022-04-14	刘志	吸入制剂及其制备方法和应用
CN114272263A (zh) *	2022-01-10	2022-04-05	伍永田	一种用于治疗高血压疾病的水配方
CN116819083B (zh) *	2023-06-20	2025-05-27	齐鲁工业大学(山东省科学院)	一种基于重组人肾素分子印迹聚合物的电化学生物传感器、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2611730A (en) *	1950-09-02	1952-09-23	Simth Kline & French Lab	Medical preparation for reducing the body level of sodium
GB1195381A (en) *	1967-04-28	1970-06-17	Arthur H Cox & Company Ltd	Pharmaceutical Compositions Comprising Potassium and Chlorine
US3639585A (en) *	1968-03-29	1972-02-01	Res Inst Medicine Chem	Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method
US3541208A (en) *	1968-09-10	1970-11-17	Arcom Holding Corp	Relief of arthritis with a soluble silicate and a soluble polyphosphate
US3921804A (en) *	1974-05-09	1975-11-25	William W Tester	Medication dispensing package
SU858830A1 (ru) *	1974-10-23	1981-08-30	Институт медико-биологических проблем	Средство дл лечени нарушений ритма сердца
SU946545A1 (ru) *	1978-05-04	1982-07-30	Институт Медико-Биологических Проблем Министерства Здравоохранения Ссср	Способ восполнени калиевого дефицита в ткан х
FR2432869A1 (fr) *	1978-08-08	1980-03-07	Armour Montagu Laboratoire	Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore
US4405596A (en) *	1978-10-16	1983-09-20	Helbig Joachim W	Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
US4289750A (en) *	1978-10-16	1981-09-15	Kopp Klaus F	Therapy of conditions which may be associated with altered renal function and dosage forms therefor
US4451454A (en) *	1981-06-16	1984-05-29	Wong Dennis W	Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
US4704269A (en) *	1985-06-11	1987-11-03	Hudson Pharmaceutical Corporation	Effervescent antacid and analgesic compositions
JPH0619063B2 (ja) *	1986-04-09	1994-03-16	日本エステル株式会社	粉体塗料用樹脂組成物

1989
- 1989-10-20 CA CA002001123A patent/CA2001123C/en not_active Expired - Fee Related
- 1989-10-20 JP JP1511794A patent/JP2948247B2/ja not_active Expired - Fee Related
- 1989-10-20 EP EP95119226A patent/EP0720855A3/de not_active Withdrawn
- 1989-10-20 DE DE68927519T patent/DE68927519T2/de not_active Expired - Fee Related
- 1989-10-20 AT AT89912571T patent/ATE145825T1/de not_active IP Right Cessation
- 1989-10-20 WO PCT/US1989/004727 patent/WO1990004402A1/en not_active Ceased
- 1989-10-20 EP EP89912758A patent/EP0461111B1/de not_active Expired - Lifetime
- 1989-10-20 AU AU46220/89A patent/AU635231B2/en not_active Ceased
- 1989-10-20 KR KR1019900701332A patent/KR0178033B1/ko not_active Expired - Fee Related
- 1989-10-20 KR KR1019900701331A patent/KR0163583B1/ko not_active Expired - Fee Related
- 1989-10-20 HU HU896889A patent/HU208923B/hu not_active IP Right Cessation
- 1989-10-20 AU AU45154/89A patent/AU634988B2/en not_active Ceased
- 1989-10-20 DE DE68913311T patent/DE68913311T2/de not_active Expired - Fee Related
- 1989-10-20 JP JP2500624A patent/JP2843146B2/ja not_active Expired - Fee Related
- 1989-10-20 CA CA002001124A patent/CA2001124C/en not_active Expired - Fee Related
- 1989-10-20 WO PCT/US1989/004771 patent/WO1990004403A1/en not_active Ceased
- 1989-10-20 HU HU896567A patent/HU212106B/hu not_active IP Right Cessation
- 1989-10-20 EP EP89912571A patent/EP0440738B1/de not_active Expired - Lifetime
- 1989-10-22 IL IL9207589A patent/IL92075A/en not_active IP Right Cessation
- 1989-10-22 IL IL9207689A patent/IL92076A/en not_active IP Right Cessation
- 1989-10-23 ZA ZA898017A patent/ZA898017B/xx unknown
- 1989-10-23 ZA ZA898018A patent/ZA898018B/xx unknown
1991
- 1991-04-19 DK DK199100727A patent/DK175840B1/da not_active IP Right Cessation
- 1991-04-19 DK DK199100726A patent/DK175841B1/da not_active IP Right Cessation
1995
- 1995-06-06 US US08/465,043 patent/US5804204A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUT63058A (en)	1993-07-28
US5804204A (en)	1998-09-08
JPH04501419A (ja)	1992-03-12
ZA898018B (en)	1990-12-28
DE68913311D1 (de)	1994-03-31
WO1990004403A1 (en)	1990-05-03
HU896567D0 (en)	1991-07-29
HU896889D0 (en)	1991-07-29
WO1990004402A1 (en)	1990-05-03
CA2001124C (en)	2000-01-18
HU208923B (en)	1994-02-28
DE68927519T2 (de)	1997-04-03
EP0440738A4 (en)	1991-08-28
KR0178033B1 (ko)	1999-03-20
EP0461111A4 (de)	1991-07-25
CA2001124A1 (en)	1990-04-21
HU212106B (en)	1996-02-28
IL92075A0 (en)	1990-07-12
EP0720855A2 (de)	1996-07-10
IL92076A (en)	1995-08-31
DK72691D0 (da)	1991-04-19
JP2948247B2 (ja)	1999-09-13
KR900701288A (ko)	1990-12-01
DE68927519D1 (de)	1997-01-16
DK72691A (da)	1991-04-22
EP0440738A1 (de)	1991-08-14
KR900701287A (ko)	1990-12-01
AU4515489A (en)	1990-05-14
DE68913311T2 (de)	1994-05-26
EP0720855A3 (de)	1998-07-08
CA2001123C (en)	2000-01-18
JP2843146B2 (ja)	1999-01-06
JPH04501724A (ja)	1992-03-26
EP0461111B1 (de)	1994-02-23
DK72791A (da)	1991-05-14
DK72791D0 (da)	1991-04-19
ZA898017B (en)	1990-12-28
AU4622089A (en)	1990-05-14
IL92076A0 (en)	1990-07-12
CA2001123A1 (en)	1990-04-21
DK175840B1 (da)	2005-03-29
EP0461111A1 (de)	1991-12-18
KR0163583B1 (ko)	1998-12-01
EP0440738B1 (de)	1996-12-04
HUT57989A (en)	1992-01-28
DK175841B1 (da)	2005-03-29
AU635231B2 (en)	1993-03-18
ATE145825T1 (de)	1996-12-15
AU634988B2 (en)	1993-03-11

Legal Events

Date	Code	Title
2000-07-16	FF	Patent granted
2000-08-31	KB	Patent renewed
2004-01-04	KB	Patent renewed
2008-11-03	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CA1308659C (en)	1992-10-13	Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
EP0440738B1 (de)	1996-12-04	Behandlung von erhöhtem Blutdruck
US5171583A (en)	1992-12-15	Treatment of osteoporosis using potassium bicarbonate
Goldberg et al.	1987	The effect of sorbitol and activated charcoal on serum theophylline concentrations after slow‐release theophylline
US5498428A (en)	1996-03-12	Treatment of hypertension by oral administration of potassium bicarbonate
US5496569A (en)	1996-03-05	Simultaneous treatment of osteoporosis and hypertension with potassium bicarbonate
US5932252A (en)	1999-08-03	Method and composition for treatment of osteoporosis
US20060052450A1 (en)	2006-03-09	Use of l-carnitine for the treatment of cardiovascular diseases
Rose et al.	1939	Effect of dihydrotachysterol in treatment of parathyroid deficiency
Upward et al.	1985	Oral labetalol in the management of stable angina pectoris in normotensive patients.
EP0691814B1 (de)	2002-06-26	Verfahren und zusammensetzungen zur behandlung der osteoporose
CA2159355C (en)	2006-12-12	Method and composition for treatment of osteoporosis
Cleghorn	1941	Recognition and treatment of Addison's disease
JPH04112823A (ja)	1992-04-14	痴呆治療剤
MacLennan et al.	1984	Disorders of the Heart
HUSSAR	1992	drugUPDATE92: NEW drugs
HK1132174A (en)	2010-02-19	Use of l-carnitine for the treatment of cardiovascular diseases